Pharm Exec Digest Europe: Issue archive

Jun 08, 2009
By Pharmaceutical Executive

OCTOBER 2010

14 October
includes:
Managing KOLs effectively
You can never be 'too digital'
Europe - a future leader in vaccines?

SEPTEMBER 2010

15 September
includes:
Is Mobile Health just for mobile people?
Recipes for Success in India and China
Why Scotland is at the forefront of life sciences investment

AUGUST 2010

25 August
includes:
Accessing the Pharmerging Markets
Global Compliance in the Pharmerging Markets
The Trouble with Stakeholders

JULY 2010

27 July
includes:
Parallel Trade in Greece and Spain
The Zombie Economy
Choosing the Right Executive for China

JUNE 2010

23 June
includes:
The Top 50 Pharma Companies
EMA concerns over NICE
Market access in Spain

9 June
includes:
EU counterfeit crossroads
Social media — a patient's story
Market access in Italy

MAY 2010

26 May
includes:
Blockbusters are alive and well
Starting out with social media
Market access in France

12 May
includes:
Listening to social media
3D competitive analysis
Market access in the UK

APRIL 2010

27 April
includes:
Do you need a social media director
Staying ahead of the technology curve
Why is the US free market so expensive?

14 April
includes:
Managing a drug crisis
New Merck's race for the emerging markets
Using the web to improve patient compliance

MARCH 2010

24 March
includes:
Nycomed's Big Pharma plans
A chronic fatigue syndrome breakthrough?
Run your sales territory as a standalone business

10 March
includes:
The lowdown of Shire
Is there life after Big Pharma?
Don't get lost in translation

FEBRUARY 2010

24 February
includes:
The future of NICE
The EU versus animal experimentation
The seven deadly sins of marketing

10 February
Includes:
Information to patients
Reinventing market research
Named patient programmes

JANUARY 2010

26 JANuaRY
includes:
Pharma to 2020
IMI UPdate with Jonathan Knowles
The art and science of marketing

13 JANuaRY
includes:
Pipeline report 20100
Recruting and retaining R&D staff in a recession
All change at the EU

NOVEMBER 2009

25 November 2009
Includes:
M&As in 2009 — Pharma’s rollercoaster year
What can pharma learn from Toyota?
Achieve more by spending — and doing — less

11 November 2009
Includes:
What will transparency mean for pharma’s reputation?
Addressing the French funding crisis
Changing the rules
Overcoming ‘them and us’ thinking

OCTOBER 2009

28 October 2009
Includes:
Industry drug lobbyists come out on top
Daniel Vasella, the inside story

14 October 2009
Includes:
CROs and pharma: a dangerously equal partnership?
Social Media: Pharma’s black hole?
Executives: It’s time to put away childish things

SEPTEMBER 2009

30 September 2009
Includes:
The obesity pipeline — a fat chance of success?
The Innovative Medicines Initiative — is it working?
What IMI round 2 means for IT

15 September 2009
Includes:
Takeda takes on Europe
Trust is more than a marketing issue
The new hot topics in supply chain management
Straddling or focusing: the moment of truth

2 September 2009
Includes:
Boost your North American business
Shark proof your product launch
Harmony in the EU?

AUGUST 2009

26 August 2009
Includes:
What's the deal at Solvay?
The power of medical animation

18 August 2009
Includes:
Need a new non-executive director?
Sweden takes the EU reins
Patent litigation insurance: a win-win situation

11 August 2009
Includes:
Seven steps to a successful global brand
EU and FDA: working together on drug approval
Profile: Erin Gainer, HRA Pharma

5 August 2009
Includes:
Chris Viehbacher: Staging a French revolution at Sanofi-Aventis
Recession proof companies Part II: Norgine
Belgium's statin plan backfires

JULY 2009

28 July 2009
Includes:
In search of recession-proof companies: Part 1
Why pharma should embrace multi-level competition
Biotech and health outcomes in 2030

21 July 2009
Includes:
The EC antitrust report results are in. Time to pop open the champagne?
The antitrust report: a legal perspective
A quick guide to the EU's new pharmacovigilance package
Does Big Pharma still exist?

14 July 2009
Includes:
Novartis: Why we can't give free flu vaccines to poor countries
Nycomed: licensing for long-term success
Keeping up with KOLs

7 July 2009
Includes:
Big Pharma isn't dead, but long live small pharma?
Where's all the specialty pharma data?
Social media CAN work for pharma

JUNE 2009

30 June 2009
Includes:
Is the online revolution working for pharma?
Tackling neglected diseases

23 June 2009
Includes:
'Pharmerging' markets and the new world order
Finding the perfect pharma match
New EU committee leaves member states out in the cold

17 June 2009
Includes:
Why are doctors so down on pharma? A 2009 survey
Smart out-licensing to survive the 'shake-out'
Too much market focus can be a bad thing

10 June 2009
Includes:
IMI's winners and losers
Knock 'em dead with your website press centre
UK Biotech: situation critical

3 June 2009
Includes:
Belgian innovation: truffles or waffle?
Opportunities in Vietnam
New pathways in R&D

MAY 2009

27 May 2009
Includes:
So, EFPIA, where's the innovative thinking, then?
Don't miss the e-Marketing boat
Only the bad times are good for pharma

20 May 2009
Includes:
The World's top 50 pharma companies

13 May 2009
Includes:
The end of European healthcare as we know it?
Biosimilars in Europe: the story so far
Strategy solutions — the answers are out there

6 May 2009
Includes:
Breaking the glass ceiling — a report on women in pharma
Reading the 'risk radar'